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Supporting Methods 
The UK Biobank Study 
 The UK Biobank study recruited over 500,000 people aged 37-73 years (99.5% were between 40 
and 69 years) from across the country in 2006-2010. Particularly focused on identifying determinants of 
human diseases in middle-aged and older individuals, participants provided a range of information (such 
as demographics, health status, lifestyle measures, cognitive testing, personality, self-report and 
physical/mental health measures) via questionnaires and interviews; anthropometric measures, BP 
readings and samples of blood, urine and saliva were taken. A full description of the study design, 
participants and quality control (QC) methods has been described in detail previously1-3. UK Biobank 
received ethical approval from the Research Ethics Committee (REC reference: 11/NW/0382). 
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 Details of patient and public involvement in the UK Biobank are available online 
(www.ukbiobank.ac.uk/about-biobank-uk/ and https://www.ukbiobank.ac.uk/wp-
content/uploads/2011/07/Summary-EGF-consultation.pdf?phpMyAdmin=trmKQlYdjj-nQIgj%2C-
fAzikMhEnx6) and is available in a pre-print version2. No patients were specifically involved in setting the 
research question or the outcome measures, nor were they involved in developing plans for recruitment, 
design or implementation of this study. No patients were asked to advise on the interpretation or writing 
up of the results. There are no specific plans to disseminate the results of the research to study 
participants, but the UK Biobank disseminates key findings from the projects on its websites. At the time 
of this study, phenotypic data were available for 502,619 participants. 
 
Measures of body mass index 
 Weight and height were collected at baseline when participants attended the initial assessment 
centre. Height (cm) was measured using a Seca 202 device in all participants in the UK Biobank along 
with sitting height. Weight (kg) was measured by a variety of means during the initial Assessment Centre 
visit, which was amalgamated into a single weight variable on the UK Biobank release data.   
A total of 13 participants had a height measurement more than 4.56 standard deviations (SDs) 
away from the mean and one person had a sitting to standing height ratio of greater than 0.75, which is 
not compatible with normal growth and development4. These participants were excluded, leaving 
500,066 valid height measurements. Of these, 499,504 participants had weight measurements available 
(no weight values were excluded).  
The UK Biobank currently has two different measures of adiposity – body mass index (BMI) 
calculated as weight divided by height squared (kg/m2) measured at the initial Assessment Centre visit 
and mass quantified using electrical impedance (in increments of 0.1kg), which was used to calculate a 
second measure of BMI. If BMI measured at the initial Assessment Centre visit was not available, the 
electrical impedance measure was used (n=255). Participants with substantial differences (>4.56 SD4) 
between impedance and normal BMI measures were excluded (n=1,164), if both measures were 
available. After these preliminary steps, 498,595 participants had a valid BMI measurement (see Figure 1 
in the main manuscript document for flow-chart of the participants used in this analysis). 
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All-cause and cause-specific mortality 
 Data from death certificates were sent to UK Biobank on a quarterly basis provided by the 
National Health Service (NHS) Information Centre for participants from England and Wales and by NHS 
Central Register, Scotland for participants from Scotland. More detailed information on mortality are 
available at http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=115559. The death certificates include the 
disease or condition stated to be the underlying cause of death, as well as other conditions, diseases, 
injuries or events contributing to death but not related to the disease or condition causing it. Data were 
provided as date of death (DoD), an integer value for age of death (AoD) and underlying (primary) cause 
of death in International Classification of Diseases (ICD)-10 codes for all deaths that occurred between 
the 10/05/2006 and 16/02/2016.  Rather than using the integer value of AoD from the death certificate, 
a more precise measure of AoD was derived by adding the time interval between date of initial 
assessment and DoD (in days) to the participant’s age at initial assessment. All participants who were not 
recorded as dead by the 16th of February 2016 were assumed to still be alive. The ICD-10 codes were 
categorised into all-cause and cause-specific mortality as presented in Table S1a. As of August 2017 (date 
of extraction for all data), there were 14,417 total deaths in the entire UK Biobank dataset that had 
occurred up to 16th of February 2016 (Table S1a for the whole sample and Table S1b for males and 
females), which remains the most updated data on mortality. 
 For the purposes of this study, the primary outcomes of focus were as follows: all-cause mortality 
and mortality from all cardiovascular diseases and those specifically due to coronary heart disease, 
stroke, aortic aneurysm and any other cardiovascular diseases; overall cancer and those specifically due 
to cancers of the lung, colorectum, prostate (men only), breast cancer (women only, separated into pre- 
and post-menopausal occurrences), pancreas, ovaries (women only), endometrium (women only), 
stomach, oesophagus, skin (malignant melanoma), kidney, bladder, brain, lymphatic system and all other 
cancers; and external causes. All other causes were combined, analysed separately and presented in 
Supporting Information. 
 
Covariables 
 At the initial UK Biobank Assessment Centre, participants were given a touchscreen 
questionnaire, which included questions about sociodemographic status, early life, sex-specific factors, 
lifestyle and environment, family history, health and medical history and psychosocial factors. Of the 
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sociodemographic questions, participants were asked whether they had any of the following 
qualifications or equivalent: i) college or university degree, ii) A/AS-levels, iii) O-levels/GCSEs, iv) CSEs, 
v) NVQ or HND or HNC, vi) other professional qualifications eg. nursing or teaching, vii) none of the listed. 
Additionally, participants were asked which of the following described their current employment 
situation: i) in paid employment or self-employed, ii) retired, iii) looking after family home and/or family, 
iv) unable to work because of sickness or disability, v) unemployed, vi) doing unpaid or voluntary work, 
vii) full or part-time student, viii) none of the listed. Answers to these questions were used to derive 
variables the represented the participants’ highest qualification level and current employment status, 
respectively.  
Of the lifestyle and environment questions, participants were asked their smoking and alcohol 
drinking status, categorised into ‘never’, ‘former or ‘current’. Participants were also asked how many days 
in a typical week they would do 10 or more minutes of vigorous physical activity (“activities that make 
you sweat or breathe hard such as fast cycling, aerobic exercise and heavy lifting”).  
 
Genotyping 
 Pre-imputation, QC, phasing and imputation of UK Biobank have been described elsewhere2, 5. 
The genetic variants used were extracted genotypes from the UK Biobank imputation dataset (using only 
genetic variants imputed to the Haplotype Reference Consortium (HRC) reference panel), which had 
extensive QC performed including exclusion of the majority of third degree or closer relatives from a 
genetic kinship analysis of 96% of participants. For more details, see http://biobank.ctsu.ox.ac.uk. A total 
of 77 common genetic variants associated with BMI within people of only European ancestry (and 
excluding those that reached genome-wide levels of statistical confidence in only one sex or one stratum) 
in the most updated genome-wide association study (GWAS) conducted by the Genetic Investigation of 
ANthropometric Traits (GIANT) consortium (comprising up to 339,224 people) were extracted for MR 
analyses (Table S2)4, 6. One SNP from the GWAS (rs12016871) was not present in the UK Biobank 
imputed genetic data, so a proxy SNP (i.e., one that is in linkage disequilibrium [LD] with rs12016871) 
was identified (rs4771122; r2=0.876, distance=2398bp) and used in replacement6. Each of the variants 
was imputed with high quality (>0.90, Table S2).  
The dosage of each genetic variant was weighted by its relative effect size on BMI obtained from 
the GIANT consortium6 and summed across all variants. The resulting total was then rescaled by dividing 
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by the sum of all effect sizes on BMI obtained from the GIANT consortium6 and multiplied by the number 
of genetic variants used. Therefore, this weighted genetic risk score (GRS) reflected the number of 
average BMI-increasing alleles each participant possessed4. In total, 487,409 participants had genetic 
data.  
 
Standard exclusions 
 After preliminary exclusions, 484,514 individuals had a valid measure of BMI, plausible age and 
death data, along with available genetic data (see Figure 1 of main manuscript document). The following 
exclusions were made to the dataset required for survival analyses prior to all analyses based on in-house 
QC parameters (total excluded = 149,206; see Figure S1 below). Individuals who were outliers in 
heterozygosity and missing rates (f.22027) were already excluded from imputed data. 
• Sex mismatch (N=367) – derived by comparing the genetic sex variable (f.22001), as determined by 
Affymetrix, with reported sex (f.31) of the participant.  
• Sex-chromosome aneuploidy (N=643) – individuals with sex chromosome karyotypes putatively 
different from XX or XY (f.22019). Of these, 177 individuals overlapped with the sex-mismatch list 
(above). 
• Relatedness – minimally related individuals were removed (N=79,034), which were defined as the first 
individual in a related pair (3rd degree or closer) based on an algorithm applied to the list of all the 
related pairs provided by UK Biobank. This number also included any individuals who appeared to be 
highly related to a very large number (>200) of individuals, derived using the list of individuals 
excluded from the kinship inference (N=9). Of these, 106 individuals overlapped with those excluded 
based on sex mismatch and sex-chromosome aneuploidy (above). Once removed, the remaining subset 
was the maximal set of unrelated individuals in UK Biobank.  
• Ancestry – stringent criteria for excluding those not of White British ancestry was used, retaining those 
who self-reported as “White” and “British” and had very similar genetic ancestry based on a principal 
components analysis of the genotypes (N=77,722). Of these, 8,277 individuals overlapped with those 
excluded based on sex mismatch, sex-chromosome aneuploidy and relatedness (above). 
 
Therefore, of those with full genetic data and information on BMI, 335,308 participants of White 
British ancestry were included in analyses after recommended exclusions based on sex mismatch, sex-
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chromosome aneuploidy detection and related individuals. Of these, 9,570 had available data on cause, 
age and date of death (see Table S1a and Figure 1 in the main manuscript).  
 
Statistical analysis 
A total of 77 common genetic variants associated with BMI within people of only European 
ancestry (and excluding those that reached genome-wide levels of statistical confidence in only one sex or 
one stratum) in the most updated genome-wide association study (GWAS) conducted by the Genetic 
Investigation of ANthropometric Traits (GIANT) consortium were extracted for MR analyses (Table S2)4, 6. 
The dosage of each genetic variant was weighted by its relative effect size on BMI in the GIANT 
consortium6 and summed across all variants. The resulting total was then rescaled such that the weighted 
genetic risk score (GRS) reflected the number of average BMI-increasing alleles each participant 
possessed4.  
As only the month and year of birth was available in the UK Biobank study, date of birth (DoB) 
was set as the 15th of each month and year in which the participant was born. Participants were removed 
if they lacked information on date of birth (used for secular trends), initial assessment age and date, cause 
of death or AoD. Participants were also excluded if they lacked any/plausible information on DoD (i.e., if 
the individual had apparently died before the assessment clinic that they later attended). Participants 
who were never at risk during the follow-up period (i.e., who were recruited after 16th February 2016) 
were also excluded.  
 
Test for endogeneity between conventional Cox regression and MR analyses 
 A simplification of the matrix method for the Durbin-Wu-Hausman (DWH) test for endogeneity 
was used to compare effect estimates derived from conventional Cox regression and Mendelian 
randomization (MR) analyses. For one instrumental variable (here, a weighted genetic risk score [GRS]), 
the test statistic can be simplified to the following formula: 
𝐻 =  
(𝛽𝐶𝐶𝑅 − 𝛽𝑀𝑅)
2
(𝑆𝐸𝐶𝐶𝑅
2 − 𝑆𝐸𝑀𝑅
2)
 
where 𝛽𝐶𝐶𝑅  and 𝛽𝑀𝑅  are the effect estimates obtained from the conventional Cox regression and MR 
analyses, respectively, and 𝑆𝐸𝐶𝐶𝑅  and 𝑆𝐸𝑀𝑅  are the corresponding standard errors. The test statistic, 𝐻, has 
a chi-squared distribution with one degree of freedom7.  
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Sensitivity analysis 
To investigate the validity of the GRS as an IV within this context, MR-Egger was used to detect 
and accommodate violations of the MR assumptions, specifically horizontal pleiotropy8. The intercept 
obtained from the MR-Egger test is used as an indication of pleiotropy and the slope can be considered as 
the estimate of the causal effect between the exposure (here, BMI) and the outcome (here, all-cause and 
cause-specific mortality). In addition, the weighted median- and mode-based methods were used9, which 
vary in their assumptions of instrument validity. The weighted median approach provides a causal 
estimate even when 50% of instruments are invalid and the weighted mode estimate is consistent when 
the largest number of similar causal effect estimates comes from valid instruments, even if most 
instruments are invalid. The MR-Egger, weighted median and weighted mode estimates were compared 
to those obtained from the inverse-variance weighted (IVW) method for two-sample MR8, 10. For these 
analyses, the first-stage estimates (coefficients of the association between each SNP and BMI) were 
obtained from an independent external source, as to not induce weak instrument bias11, 12, and the 
second-stage estimates (natural logarithm of the HR for each mortality outcome with each SNP, , adjusted 
for secular trend and the first ten genetic principal components) were obtained directly from UK Biobank. 
In the UK Biobank sample, there is evidence to suggest a differential array effect on markers 
scattered across the genome (i.e., those that were genotyped using the Affymetrix UK Biobank Axiom® 
Array or the Affymetrix UK BiLEVE Axiom Array2, 5) and the UK BiLEVE sub-sample, which included 
>50,000 participants and used the UK BiLEVE Axiom Array, also preferentially selected individuals based 
on smoking intensity. To evaluate the impact of this differential array effect, and the confounding factors 
associated with the GRS, MR sensitivity analyses were conducted with adjustment for these additional 
covariables. 
As a final sensitivity analysis, the GRS was restricted to exclude the genetic variants known to be 
classified as having a secondary signal within a locus to other phenotypes (N=7; leaving 70 in the GRS, 
Table S3)4, 13 and all MR analyses were repeated.  
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Table S1a. Descriptive statistics for UK Biobank mortality data 
Cause of death ICD10 codes 
Total number of deaths in UK Biobank 
Whole sample With valid data White British 
All-cause All 14,417 11,161 9,570 
Cardiovascular disease1 I*; G459 2,999 2,332 1,967 
Coronary heart disease2 I209-I259; I516 1,661 1,291 1,087 
Stroke3 I600-I698; G459 550 428 346 
Aortic aneurysm I710-I719 152 120 109 
Other cardiovascular diseases All other I 636 493 425 
Diabetes4 E10-E149 70 50 37 
Respiratory diseases5 J* 834 631 532 
Cancer6 C* 8,286 6,484 5,613 
Lung cancer C33-C349 1,507 1,160 993 
Breast cancer C50-C509 739 560 472 
Prostate cancer C61-C619 440 348 308 
Colorectal cancer C180-C219 822 646 552 
Pancreatic cancer C250-C259 556 446 388 
Stomach cancer C160-C169 201 162 144 
Ovarian cancer C56-C570 306 247 211 
Endometrial cancer C54-C549 76 56 50 
Gallbladder cancer C23-C249 55 41 37 
Oesophageal cancer C15-C159 389 310 283 
Malignant melanoma C43-C449 173 131 119 
Thyroid cancer C73-C739 16 11 9 
Kidney cancer C64-C669 245 196 181 
Bladder cancer C67-C679 161 122 101 
Brain cancer C71-C729 408 322 280 
Liver cancer C220-C229 266 208 169 
Cervical cancer C53-C539 16 13 12 
Uterine cancer C55-C559 40 29 21 
Lymphatic cancer C810-C964 730 592 528 
Other cancers All other C 1,140 884 755 
Kidney disease N00-N299 34 23 16 
External causes7 V*; W*; X*; Y* 496 359 306 
Other causes8 - 1,698 1,282 1,099 
ICD = International Classification of Diseases 
Mortality causes in bold were not included in analyses due to small number of deaths (<40): cancer of the 
gallbladder (N=37), thyroid (N=9), cervix (N=12) and uterus (N=21) and kidney disease (N=16) 
*Any code beginning with the indicated letter 
1Cardiovascular disease consisted of all disease of the circulatory system listed in ICD 10, including coronary 
heart disease and stroke. 
2Coronary heart disease is a narrowing of the arteries supplying the heart muscle and may be considered 
synonymous with ischemic heart disease or coronary artery disease. 
3Stroke included bleeding from (haemorrhagic stroke) or blockage of (ischemic stroke) the arteries 
supplying the brain, as well as transient ischemic attacks (“mini-strokes”). 
4Diabetes included insulin-dependent and non-insulin-dependent diabetes mellitus. 
5Respiratory diseases included all non-neoplasmic diseases of the lungs, pleura and respiratory tract. 
6Cancers excluded benign or in-situ neoplasms. 
7External causes consisted of accidents and violence, including suicide and conditions consequent to 
accidents and violence 
8Other causes included all other causes of mortality not otherwise listed. 
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Table S1b. Descriptive statistics for UK Biobank mortality data stratified by sex 
Cause of death ICD10 codes 
Total number of deaths in UK Biobank 
(with valid data for main analyses) 
Males Females 
All-cause All 5,882 3,688 
Cardiovascular disease1 I*; G459 1,467 500 
Coronary heart disease2 I209-I259; I516 906 181 
Stroke3 I600-I698; G459 194 152 
Aortic aneurysm I710-I719 83 26 
Other cardiovascular diseases All other I 284 141 
Diabetes4 E10-E149 29 8 
Respiratory diseases5 J* 361 171 
Cancer6 C* 3,113 2,500 
Lung cancer C33-C349 571 422 
Breast cancer C50-C509 4 468 
Prostate cancer C61-C619 308 - 
Colorectal cancer C180-C219 329 223 
Pancreatic cancer C250-C259 201 187 
Stomach cancer C160-C169 105 39 
Ovarian cancer C56-C570 - 211 
Endometrial cancer C54-C549 - 50 
Gallbladder cancer C23-C249 16 21 
Oesophageal cancer C15-C159 226 57 
Malignant melanoma C43-C449 78 41 
Thyroid cancer C73-C739 2 7 
Kidney cancer C64-C669 137 44 
Bladder cancer C67-C679 78 23 
Brain cancer C71-C729 169 111 
Liver cancer C220-C229 100 69 
Cervical cancer C53-C539 - 12 
Uterine cancer C55-C559 - 21 
Lymphatic cancer C810-C964 329 199 
Other cancers All other C 460 295 
Kidney disease N00-N299 10 6 
External causes7 V*; W*; X*; Y* 206 100 
Other8 - 696 403 
ICD = International Classification of Diseases 
In addition to the mortality causes with a collectively small number of deaths in the whole sample (Table 
S1a), the sex-specific mortality causes in bold were also not included in analyses due to small numbers of 
deaths (<40) when stratified by sex: aortic aneurysm in females (N=26), diabetes (N=29/8 in males/females, 
respectively), breast cancer in males (N=4) and cancer of the stomach in females (N=39), gallbladder 
(N=16/21 in males/females, respectively) and bladder in females (N=23). 
*Any code beginning with the indicated letter 
1Cardiovascular disease consisted of all disease of the circulatory system listed in ICD 10, including coronary 
heart disease and stroke. 
2Coronary heart disease is a narrowing of the arteries supplying the heart muscle and may be considered 
synonymous with ischemic heart disease or coronary artery disease. 
3Stroke included bleeding from (haemorrhagic stroke) or blockage of (ischemic stroke) the arteries 
supplying the brain, as well as transient ischemic attacks (“mini-strokes”). 
4Diabetes included insulin-dependent and non-insulin-dependent diabetes mellitus. 
5Respiratory diseases included all non-neoplasmic diseases of the lungs, pleura and respiratory tract. 
6Cancers excluded benign or in-situ neoplasms. 
7External causes consisted of accidents and violence, including suicide and conditions consequent to 
accidents and violence 
8Other causes included all other causes of mortality not otherwise listed.  
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Table S2. Genetic variants (N=77) associated with BMI in the GIANT consortium and available in UK Biobank individuals (N=335,308) 
Genetic variant Gene Chr bp Effect allele1 Other allele1 EAF2 Beta (SE)3 P-value3 
Imputation 
quality2 
rs1000940 RABEP1 17 5283252 G A 0.30 0.07 (0.01) 1.45x10-07 0.998 
rs10132280 STXBP6 14 25928179 C A 0.70 0.11 (0.01) 2.54x10-17 0.988 
rs1016287 LINC01122 2 59305625 T C 0.30 0.10 (0.01) 1.04x10-14 0.997 
rs10182181 ADCY3 2 25150296 G A 0.49  0.17 (0.01) 1.42x10-48 0.996 
rs10733682 LMX1B 9 129460914 A G 0.47 0.06 (0.01) 1.63x10-07 0.962 
rs10938397 GNPDA2 4 45182527 G A 0.43 0.14 (0.01) 9.04x10-34 1.000 
rs10968576 LINGO2 9 28414339 G A 0.31 0.12 (0.01) 7.92x10-23 1.000 
rs11030104 BDNF 11 27684517 A G 0.80 0.18 (0.01) 1.77x10-35 0.999 
rs11057405 CLIP1 12 122781897 G A 0.90 0.14 (0.02) 3.10x10-14 1.000 
rs11126666 KCNK3 2 26928811 A G 0.26 0.02 (0.01) 0.16 0.995 
rs11165643 PTBP2 1 96924097 T C 0.58 0.08 (0.01) 9.47x10-13 0.998 
rs11191560 NT5C2 10 104869038 C T 0.08 0.12 (0.02) 1.42x10-08 0.999 
rs11583200 ELAVL4 1 50559820 C T 0.40 0.07 (0.01) 1.78x10-09 0.993 
rs1167827 HIP1 7 75163169 G A 0.57 0.11 (0.01) 6.81x10-20 1.000 
rs11688816 EHBP1 2 63053048 G A 0.54 0.06 (0.01) 1.76x10-07 0.993 
rs11727676 HHIP 4 145659064 T C 0.91 0.04 (0.02) 0.03 1.000 
rs11847697 PRKD1 14 30515112 T C 0.05 0.12 (0.03) 3.99x10-05 1.000 
rs12286929 CADM1 11 115022404 G A 0.52 0.08 (0.01) 9.79x10-11 0.996 
rs12401738 FUBP1 1 78446761 A G 0.33 0.07 (0.01) 4.54x10-10 0.995 
rs12429545 OLFM4 13 54102206 A G 0.13 0.13 (0.02) 3.38x10-13 0.979 
rs12446632 GPRC5B 16 19935389 G A 0.86 0.13 (0.02) 1.77x10-15 1.000 
rs12566985 FPGT-TNNI3K 1 75002193 G A 0.45 0.07 (0.01) 1.14x10-09 0.998 
rs12885454 PRKD1 14 29736838 C A 0.65 0.07 (0.01) 1.82x10-09 0.998 
rs12940622 RPTOR 17 78615571 G A 0.56 0.08 (0.01) 2.83x10-12 0.999 
rs13021737 TMEM18 2 632348 G A 0.83 0.25 (0.02) 6.91x10-59 1.000 
rs13078960 CADM2 3 85807590 G T 0.20 0.10 (0.01) 4.96x10-11 0.994 
rs13107325 SLC39A8 4 103188709 T C 0.07 0.25 (0.02) 2.82x10-29 1.000 
rs13191362 PARK2 6 163033350 A G 0.88 0.10 (0.02) 7.79x10-09 0.995 
rs1516725 ETV5 3 185824004 C T 0.86 0.16 (0.02) 6.64x10-22 0.992 
rs1528435 UBE2E3 2 181550962 T C 0.62 0.08 (0.01) 4.57x10-11 0.997 
rs1558902 FTO 16 53803574 A T 0.39 0.36 (0.01) 5.55x10-201 1.000 
rs16851483 RASA2 3 141275436 T G 0.07 0.17 (0.02) 3.36x10-13 0.998 
rs16951275 MAP2K5 15 68077168 T C 0.77 0.14 (0.01) 9.63x10-23 0.999 
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rs17001654 SCARB2 4 77129568 G C 0.15 0.09 (0.02) 2.65x10-07 0.973 
rs17024393 GNAT2 1 110154688 C T 0.03 0.31 (0.04) 1.15x10-17 0.998 
rs17094222 HIF1AN 10 102395440 C T 0.21 0.07 (0.01) 4.01x10-07 0.991 
rs17405819 HNF4G 8 76806584 T C 0.71 0.09 (0.01) 9.08x10-14 1.000 
rs17724992 PGPEP1 19 18454825 A G 0.73 0.08 (0.01) 2.93x10-09 0.991 
rs1808579 C18orf8 18 21104888 C T 0.52 0.10 (0.01) 3.91x10-18 0.998 
rs1928295 TLR4 9 120378483 T C 0.57 0.06 (0.01) 1.49x10-06 1.000 
rs2033529 TDRG1 6 40348653 G A 0.28 0.11 (0.01) 3.39x10-17 0.992 
rs2033732 RALYL 8 85079709 C T 0.75 0.05 (0.01) 9.75x10-05 1.000 
rs205262 C6orf106 6 34563164 G A 0.27 0.14 (0.01) 1.36x10-27 0.998 
rs2075650 TOMM40 19 45395619 A G 0.85 0.09 (0.02) 1.39x10-07 1.000 
rs2112347 POC5 5 75015242 T G 0.63 0.14 (0.01) 2.21x10-29 1.000 
rs2121279 LRP1B 2 143043285 T C 0.12 0.06 (0.02) 0.002 0.991 
rs2176598 HSD17B12 11 43864278 T C 0.25 0.09 (0.01) 4.92x10-12 1.000 
rs2207139 TFAP2B 6 50845490 G A 0.17 0.20 (0.02) 9.44x10-37 1.000 
rs2245368 PMS2L11 7 76608143 C T 0.18 0.11 (0.02) 1.30x10-13 1.000 
rs2287019 QPCTL 19 46202172 C T 0.82 0.15 (0.02) 1.36x10-24 0.984 
rs2365389 FHIT 3 61236462 C T 0.58 0.08 (0.01) 2.94x10-11 0.994 
rs2650492 SBK1 16 28333411 A G 0.29 0.09 (0.01) 8.10x10-12 0.988 
rs2820292 NAV1 1 201784287 C A 0.56 0.10 (0.01) 9.50x10-17 1.000 
rs29941 KCTD15 19 34309532 G A 0.67 0.08 (0.01) 9.01x10-10 1.000 
rs3101336 NEGR1 1 72751185 C T 0.61 0.10 (0.01) 1.10x10-18 1.000 
rs3736485 DMXL2 15 51748610 A G 0.47 0.06 (0.01) 6.19x10-07 0.995 
rs3810291 ZC3H4 19 47569003 A G 0.66 0.13 (0.01) 2.87x10-26 1.000 
rs3817334 MTCH2 11 47650993 T C 0.40 0.12 (0.01) 8.11x10-23 1.000 
rs3849570 GBE1 3 81792112 A C 0.35 0.06 (0.01) 2.36x10-06 1.000 
rs3888190 ATP2A1 16 28889486 A C 0.39 0.13 (0.01) 7.39x10-28 1.000 
rs4256980 TRIM66 11 8673939 G C 0.65 0.08 (0.01) 8.96x10-12 0.996 
rs4740619 C9orf93 9 15634326 T C 0.55 0.09 (0.01) 3.62x10-14 0.999 
rs4771122* MTIF3 13 28020180 G A 0.22 0.04 (0.01) 0.01 1.000 
rs543874 SEC16B 1 177889480 G A 0.20 0.23 (0.01) 2.11x10-58 1.000 
rs6477694 EPB41L4B 9 111932342 C T 0.36 0.06 (0.01) 1.80x10-06 0.990 
rs6567160 MC4R 18 57829135 C T 0.23 0.25 (0.01) 6.70x10-75 0.998 
rs657452 AGBL4 1 49589847 A G 0.40 0.08 (0.01) 1.88x10-11 0.987 
rs6804842 RARB 3 25106437 G A 0.57 0.05 (0.01) 4.39x10-06 0.991 
rs7138803 BCDIN3D 12 50247468 A G 0.36 0.13 (0.01) 1.95x10-28 1.000 
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rs7141420 NRXN3 14 79899454 T C 0.52 0.10 (0.01) 1.05x10-17 0.985 
rs7243357 GRP 18 56883319 T G 0.82 0.09 (0.02) 9.42x10-09 0.990 
rs758747 NLRC3 16 3627358 T C 0.29 0.06 (0.01) 9.10x10-06 0.978 
rs7599312 ERBB4 2 213413231 G A 0.73 0.08 (0.01) 7.13x10-09 0.979 
rs7899106 GRID1 10 87410904 G A 0.05 0.13 (0.03) 1.68x10-06 0.987 
rs7903146 TCF7L2 10 114758349 C T 0.71 0.08 (0.01) 1.04x10-10 1.000 
rs9400239 FOXO3 6 108977663 C T 0.69 0.08 (0.01) 3.48x10-10 0.994 
rs9925964 KAT8 16 31129895 A G 0.65 0.12 (0.01) 1.97x10-24 0.998 
BMI = body mass index; bp = base pair; Chr = chromosome; EAF = effect allele frequency; GIANT = Genetic Investigation of ANthropometric Traits; SE = standard error 
1Effect and other alleles associated with an increasing BMI, according to the most recent genome-wide association study of BMI6  
2Minor allele frequency (MAF) of each genetic variant in UK Biobank and corresponding imputation quality (the latter of which was based on the whole of UK Biobank) 
3Beta and corresponding standard error (SE) and P-value represent the change in BMI (kg/m2) per BMI-increasing allele of each genetic variant in individuals of White 
British ancestry adjusted for the first ten genetic principal components. 
*The rs4771122 SNP served as the closest proxy (with an r2=0.876, distance=2398bp), according to SNAP (http://archive.broadinstitute.org/mpg/snap/ldsearch.php) 
for the rs12016871 on chromosome 13, which was not available in the UK Biobank genetic data.   
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Table S3. Genetic variants excluded in from sensitivity analyses 
SNP Gene Chromosome Reason for exclusion 
rs977747 TAL1 1 All ancestries 
rs1460676 FIGN 2 All ancestries 
rs17203016 CREB1 2 All ancestries 
rs2176040 LOC646736 2 European men 
rs492400 USP37 2 European men 
rs13107325 SLC39A8 4 Pleiotropic effects 
rs17001654 SCARB2 4 Pleiotropic effects 
rs7715256 GALNT10 5 All ancestries 
rs13201877 IFNGR1 6 All ancestries 
rs9374842 LOC285762 6 European population based 
rs1167827 HIP1 7 Pleiotropic effects 
rs6465468 ASB4 7 European women 
rs9641123 CALCR 7 European population based 
rs16907751 ZBTB10 8 European men 
rs7903146 TCF7L2 10 Identified in Corbin et al.13 
rs11030104 BDNF 11 Pleiotropic effects 
rs1441264 MIR548A2 13 All ancestries 
rs9540493 MIR548X2 13 European population based 
rs7164727 LOC100287559 15 All ancestries 
rs2080454 CBLN1 16 All ancestries 
rs3888190 ATP2A1 16 Pleiotropic effects 
rs4787491 INO80E 16 European population based 
rs9914578 SMG6 17 All ancestries 
rs7239883 LOC284260 18 European women 
rs2075650 TOMM40 19 Pleiotropic effects 
rs6091540 ZFP64 20 European women 
rs2836754 ETS2 21 All ancestries 
Consistent with previous studies4, 13, 14, these genetic variants were excluded in sensitivity analyses to test the 
robustness of the GRS used in MR analyses
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Table S4. Association of participants’ characteristics with BMI 
Variable N Estimate (95% CI)1 P-value 
Age (years) 335,308 0.03 (0.03, 0.03) 1.15x10-171 
Sex (% of males) 335,308 0.81 (0.78, 0.84) <1.20x10-307 
Smoking status 334,142   
Never  reference  
Former  0.81 (0.78, 0.85) <1.20x10-307 
Current  -0.04 (-0.10, 0.01) 0.11 
Alcohol drinker status 335,074   
Never  reference  
Former  0.29 (0.16, 0.41) 8.86x10-06 
Current  -0.68 (-0.77, -0.59) 9.22x10-47 
Highest qualifications  275,544   
College or University degree  reference  
A-levels  0.59 (0.54, 0.64) 5.98x10-101 
O-levels  1.00 (0.96, 1.05) <1.20x10-307 
CSEs  1.49 (1.42, 1.56) <1.20x10-307 
NVQ/HND/HNC  1.71 (1.64, 1.78) <1.20x10-307 
Other professional qualifications  1.17 (1.09, 1.24) 4.16x10-205 
Current employment status 332,835   
In paid employment or self-employed  reference  
Retired  0.27 (0.24, 0.31) 4.55x10-55 
Looking after home/family  -0.70 (-0.80, -0.60) 7.82x10-42 
Unable to work due to sickness/disability  2.50 (2.40, 2.59) <1.20x10-307 
Unemployed  0.84 (0.70, 0.98) 1.77x10-31 
Doing unpaid or voluntary work  -0.74 (-0.99, -0.49) 5.50x10-09 
Full or part-time student  -0.75 (-1.13, -0.38) 6.94x10-05 
Days/week spent doing vigorous physical activity 319,813 -0.24 (-0.24, -0.23) <1.20x10-307 
Genotyping chip2 335,308 0.61 (0.55, 0.66) 7.02x10-102 
BMI = body mass index; CI = confidence interval; CSE = certificate of secondary education; HNC = higher 
national certificate; HND = higher national diploma; NVQ = national vocational qualification 
1Estimates represent the difference in BMI (kg/m2) per unit increase in each continuous, categorical or 
binary variable in individuals of White British ancestry. 
2There was evidence of differential array effect on markers scattered across the genome; therefore, the UK 
BiLEVE study genotyped on the Affymetrix Axiom Array was considered as a covariable 
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Table S5. Association of participants’ characteristics and all-cause mortality 
Variable HR (95% CI)1 P-value 
Age (years) 0.95 (0.94, 0.96) 2.01x10-20 
Sex (% of males) 1.79 (1.72, 1.87) 2.47x10-169 
Smoking status   
Never reference  
Former 1.52 (1.45, 1.59) 2.09x10-72 
Current 3.26 (3.08, 3.45) <1.20x10-307 
Alcohol drinker status   
Never reference  
Former 1.88 (1.66, 2.14) 3.39x10-22 
Current 0.93 (0.84, 1.03) 0.17 
Highest qualifications    
College or University degree reference  
A-levels 1.10 (1.02, 1.19) 0.02 
O-levels 1.10 (1.03, 1.17) 0.003 
CSEs 1.34 (1.20, 1.51) 3.38x10-07 
NVQ/HND/HNC 1.35 (1.24, 1.46) 3.27x10-12 
Other professional qualifications 1.13 (1.03, 1.24) 0.01 
Current employment status   
In paid employment or self-employed reference  
Retired 1.12 (1.06, 1.19) 7.82x10-05 
Looking after home/family 1.04 (0.87, 1.23) 0.68 
Unable to work due to sickness/disability 5.18 (4.80, 5.59) <1.20x10-307 
Unemployed 2.29 (1.93, 2.70) 3.61x10-22 
Doing unpaid or voluntary work 0.85 (0.58, 1.24) 0.39 
Full or part-time student 1.93 (1.12, 3.33) 0.02 
Days/week spent doing vigorous physical activity 0.94 (0.93, 0.95) 1.40x10-29 
Genotyping chip2 1.34 (1.26, 1.42) 2.21x10-20 
CI = confidence interval; CSE = certificate of secondary education; HNC = higher national certificate; HND = 
higher national diploma; HR = hazard ratio; NVQ = national vocational qualification 
1Estimates represent the difference in hazards for all-cause mortality per unit increase in each continuous, 
categorical or binary variable in individuals of White British ancestry. 
2There was evidence of differential array effect on markers scattered across the genome; therefore, the UK 
BiLEVE study genotyped on the Affymetrix Axiom Array was added as a covariable 
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Table S6. Association of participants’ characteristics and the weighted GRS (comprising 77 SNPs) 
Variable N Estimate (95% CI)1 P-value 
Age (years) 335,308 -0.002 (-0.004, 0.0003) 0.09 
Sex (% of males) 335,308 0.03 (-0.003, 0.07) 0.07 
Smoking status 334,142   
Never  reference  
Former  0.15 (0.11, 0.19) 9.45x10-13 
Current  0.23 (0.16, 0.29) 6.68x10-12 
Alcohol drinker status 335,074   
Never  reference  
Former  0.11 (-0.04, 0.25) 0.16 
Current  -0.12 (-0.22, -0.01) 0.04 
Highest qualifications  275,544   
College or University degree  reference  
A-levels  0.01 (-0.05, 0.07) 0.76 
O-levels  0.10 (0.04, 0.15) 2.88x10-04 
CSEs  0.20 (0.11, 0.29) 8.29x10-06 
NVQ/HND/HNC  0.19 (0.11, 0.27) 5.80x10-06 
Other professional qualifications  0.10 (0.01, 0.19) 0.02 
Current employment status 332,835   
In paid employment or self-employed  reference  
Retired  0.02 (-0.03, 0.06) 0.46 
Looking after home/family  -0.15 (-0.27, -0.03) 0.01 
Unable to work due to sickness/disability  0.30 (0.19, 0.41) 1.28x10-07 
Unemployed  0.03 (-0.14, 0.19) 0.74 
Doing unpaid or voluntary work  0.12 (-0.17, 0.41) 0.42 
Full or part-time student  0.07 (-0.37, 0.50) 0.75 
Days/week spent doing vigorous physical activity 319,813 0.01 (0.002, 0.02) 0.02 
Genotyping chip2 335,308 0.15 (0.09, 0.22) 3.47x10-06 
BMI = body mass index; CI = confidence interval; CSE = certificate of secondary education; GRS = genetic risk 
score; HNC = higher national certificate; HND = higher national diploma; NVQ = national vocational 
qualification; SNP = single nucleotide polymorphism 
1Estimates represent the difference in the GRS (comprising 77 SNPs) per unit increase in each continuous, 
categorical or binary variable in individuals of White British ancestry adjusted for the first ten genetic 
principal components. 
2There was evidence of differential array effect on markers scattered across the genome; therefore, the UK 
BiLEVE study genotyped on the Affymetrix Axiom Array was added as a covariable 
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Table S7. MR analyses of higher BMI on mortality from all other causes in UK Biobank participants of White British ancestry  
Sample N1 
Observational 
MR-analyses DWH5 
Unadjusted Adjusted 
HR (95% CI)2 P-value HR (95% CI)3 P-value HR (95% CI)4 P-value  
Whole sample 1,099 1.02 (1.00, 1.03) 0.01 1.01 (0.99, 1.02) 0.31 1.01 (0.90, 1.13) 0.87 0.91 
Males 696 1.00 (0.99, 1.02) 0.65 0.99 (0.97, 1.01) 0.44 0.97 (0.84, 1.12) 0.70 0.65 
Females 403 1.02 (1.00, 1.04) 0.04 1.02 (1.00, 1.04) 0.08 1.07 (0.89, 1.29) 0.44 0.58 
BMI = body mass index; CI = confidence interval; HR = hazard ratio 
1Number of deaths from all other causes  
2Adjusted for secular trends (date of birth), estimates represent HR with each unit increase in BMI (kg/m2) 
3Adjusted for secular trends (date of birth), highest household occupation, education, smoking status, alcohol intake and physical activity 
4Adjusted for secular trends (date of birth) and the first ten genetic principal components  
5P-value for comparing estimates derived from observational and MR analyses using a simplification of the matrix method for DWH test statistic (see Supporting 
Methods))
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Table S8a. Statistical test of the proportional hazards assumption in conventional Cox regression  
Cause of death 
Correlation coefficient (and corresponding P-
values) for the test of proportional hazards1 
Whole sample Males Females 
All-cause -0.004 (0.76) 0.003 (0.87) -0.02 (0.42) 
Cardiovascular disease -0.08 (0.01) -0.06 (0.08) -0.12 (0.04) 
Coronary heart disease -0.01 (0.79) 0.01 (0.75) -0.10 (0.36) 
Stroke 0.03 (0.66) 0.05 (0.57) -0.005 (0.96) 
Aortic aneurysm -0.28 (0.02) -0.30 (0.02) - 
Other cardiovascular diseases -0.18 (0.003) -0.17 (0.02) -0.19 (0.08) 
Respiratory diseases -0.07 (0.22) 0.01 (0.94) -0.10 (0.36) 
Cancer 0.02 (0.23) 0.03 (0.21) 0.003 (0.89) 
Lung cancer 0.04 (0.36) 0.15 (0.01) -0.07 (0.25) 
Prostate cancer - -0.06 (0.38) - 
Breast cancer - - 0.10 (0.06) 
Pre-menopausal - - 0.23 (0.13) 
Post-menopausal - - 0.11 (0.05) 
Colorectal cancer -0.004 (0.93) -0.001 (0.99) -0.001 (0.99) 
Pancreatic cancer -0.10 (0.11) -0.06 (0.45) -0.13 (0.15) 
Stomach cancer 0.002 (0.98) 0.12 (0.35) - 
Ovarian cancer - - -0.10 (0.21) 
Endometrial cancer - - 0.27 (0.13) 
Oesophageal cancer -0.07 (0.33) -0.08 (0.34) 0.06 (0.70) 
Malignant melanoma -0.10 (0.34) -0.05 (0.71) -0.12 (0.51) 
Kidney cancer 0.09 (0.33) 0.10 (0.35) 0.09 (0.67) 
Bladder cancer -0.15 (0.24) -0.12 (0.37) - 
Brain cancer 0.04 (0.58) 0.004 (0.97) 0.11 (0.31) 
Liver cancer -0.02 (0.87) -0.003 (0.98) -0.09 (0.54) 
Lymphatic cancer -0.02 (0.69) 0.005 (0.94) -0.06 (0.46) 
Other cancer 0.08 (0.06) 0.08 (0.15) 0.09 (0.21) 
External causes 0.06 (0.33) 0.04 (0.64) 0.10 (0.37) 
1Values represent the Pearson’s correlation coefficient (and corresponding P-values) between the first scaled 
Schoenfeld residual (obtained from the survival analysis of BMI on each mortality outcome adjusted for 
secular trends (date of birth), highest household occupation, education, smoking status, alcohol intake and 
physical activity) in conventional Cox regression and the rank-normalised natural logarithm of follow-up 
time (age). Positive/negative values suggest that the relationship between BMI and mortality 
increases/decreases over the follow-up period, respectively.  
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Table S8b. Statistical test of the proportional hazards assumption using Mendelian randomization 
Cause of death 
Correlation coefficient (and corresponding P-
values) for the test of proportional hazards1 
Whole sample Males Females 
All-cause 0.01 (0.22) 0.02 (0.22) 0.01 (0.57) 
Cardiovascular disease -0.003 (0.90) 0.02 (0.50) -0.05 (0.24) 
Coronary heart disease -0.02 (0.50) -0.004 (0.91) -0.09 (0.25) 
Stroke 0.08 (0.13) 0.15 (0.04) 0.001 (0.99) 
Aortic aneurysm 0.10 (0.29) 0.15 (0.18) - 
Other cardiovascular diseases -0.03 (0.56) -0.01 (0.83) -0.06 (0.51) 
Respiratory diseases -0.01 (0.90) 0.03 (0.60) -0.07 (0.39) 
Cancer 0.02 (0.09) 0.02 (0.33) 0.03 (0.16) 
Lung cancer -0.02 (0.49) -0.01 (0.90) -0.04 (0.39) 
Prostate cancer - 0.12 (0.03) - 
Breast cancer - - 0.01 (0.79) 
Pre-menopausal - - 0.07 (0.62) 
Post-menopausal - - -0.004 (0.93) 
Colorectal cancer 0.06 (0.13) 0.02 (0.75) 0.13 (0.05) 
Pancreatic cancer 0.06 (0.25) 0.08 (0.24) 0.04 (0.60) 
Stomach cancer 0.07 (0.39) 0.05 (0.64) - 
Ovarian cancer - - -0.11 (0.12) 
Endometrial cancer - - 0.14 (0.33) 
Oesophageal cancer -0.05 (0.41) -0.04 (0.58) -0.09 (0.52) 
Malignant melanoma 0.19 (0.04) 0.24 (0.03) 0.07 (0.64) 
Kidney cancer -0.04 (0.61) -0.04 (0.68) -0.07 (0.65) 
Bladder cancer 0.13 (0.18) 0.12 (0.29) - 
Brain cancer 0.01 (0.82) -0.07 (0.35) 0.16 (0.10) 
Liver cancer -0.14 (0.07) -0.17 (0.08) -0.09 (0.48) 
Lymphatic cancer -0.01 (0.85) 0.01 (0.90) -0.03 (0.70) 
Other cancer 0.05 (0.14) 0.04 (0.36) 0.08 (0.19) 
External causes 0.09 (0.12) 0.08 (0.27) 0.16 (0.12) 
1Values represent the Pearson’s correlation coefficient (and corresponding P-values) between the first scaled 
Schoenfeld residual (obtained from the survival analysis of BMI on each mortality outcome adjusted for 
secular trends (date of birth) and the first ten genetic principal components) in Mendelian randomization 
analyses and the rank-normalised natural logarithm of follow-up time (age). Positive/negative values 
suggest that the relationship between BMI and mortality increases/decreases over the follow-up period, 
respectively.
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Table S9a. MR-Egger analysis of BMI on all-cause and cause-specific mortality in UK Biobank participants of White British ancestry 
Cause of death 
IVW Intercept of MR-Egger MR-Egger Weighted median Weighted mode 
HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P 
All-cause 1.02 (0.99, 1.06) 0.25 1.00 (0.99, 1.01) 0.72 1.04 (0.95, 1.13) 0.43 1.04 (0.98, 1.08) 0.26 1.04 (0.98, 1.11) 0.16 
Cardiovascular disease 1.07 (1.00, 1.15) 0.05 1.00 (0.98, 1.02) 0.90 1.06 (0.89, 1.26) 0.49 1.08 (0.96, 1.18) 0.24 1.20 (1.03, 1.39) 0.02 
Coronary heart disease 1.09 (0.99, 1.20) 0.08 1.00 (0.97, 1.03) 0.78 1.12 (0.89, 1.42) 0.33 1.06 (0.94, 1.25) 0.28 1.08 (0.90, 1.29) 0.44 
Stroke 0.98 (0.84, 1.15) 0.83 1.02 (0.97, 1.08) 0.41 0.85 (0.57, 1.26) 0.40 0.92 (0.72, 1.14) 0.41 0.82 (0.59, 1.14) 0.24 
Aortic aneurysm 0.86 (0.64, 1.16) 0.33 1.05 (0.95, 1.15) 0.34 0.62 (0.29, 1.31) 0.21 0.80 (0.50, 1.24) 0.30 0.82 (0.47, 1.44) 0.49 
Other cardiovascular diseases  1.18 (1.02, 1.35) 0.02 0.99 (0.94, 1.03) 0.52 1.30 (0.92, 1.84) 0.13 1.18 (0.95, 1.52) 0.13 1.22 (0.90, 1.66) 0.20 
Respiratory diseases 1.03 (0.90, 1.18) 0.69 1.02 (0.98, 1.07) 0.34 0.88 (0.63, 1.24) 0.47 0.94 (0.79, 1.18) 0.70 0.88 (0.67, 1.17) 0.40 
Cancer 0.99 (0.95, 1.03) 0.69 1.00 (0.99, 1.01) 0.98 0.99 (0.90, 1.10) 0.90 1.01 (0.94, 1.07) 0.86 1.01 (0.94, 1.10) 0.76 
Lung cancer 0.97 (0.89, 1.06) 0.51 1.02 (0.99, 1.05) 0.24 0.86 (0.68, 1.08) 0.18 0.95 (0.83, 1.11) 0.51 0.94 (0.77, 1.14) 0.51 
Colorectal cancer 1.05 (0.91, 1.20) 0.49 1.02 (0.97, 1.06) 0.48 0.94 (0.67, 1.32) 0.71 1.07 (0.87, 1.29) 0.56 1.09 (0.86, 1.39) 0.47 
Pancreatic cancer 1.07 (0.92, 1.25) 0.35 1.03 (0.98, 1.08) 0.25 0.88 (0.60, 1.28) 0.51 1.00 (0.82, 1.31) 0.81 1.01 (0.77, 1.34) 0.93 
Stomach cancer 1.15 (0.91, 1.46) 0.24 0.94 (0.87, 1.02) 0.13 1.74 (0.97, 3.11) 0.06 1.58 (0.94, 1.97) 0.10 1.68 (0.99, 2.86) 0.06 
Oesophageal cancer 1.17 (0.98, 1.39) 0.08 0.99 (0.93, 1.04) 0.66 1.28 (0.83, 1.97) 0.26 1.00 (0.83, 1.47) 0.49 1.02 (0.70, 1.49) 0.91 
Malignant melanoma 1.15 (0.88, 1.51) 0.31 1.04 (0.95, 1.13) 0.38 0.87 (0.44, 1.71) 0.69 0.89 (0.68, 1.56) 0.89 1.02 (0.62, 1.69) 0.94 
Kidney cancer 0.95 (0.77, 1.18) 0.65 1.03 (0.96, 1.10) 0.46 0.79 (0.47, 1.35) 0.39 1.02 (0.67, 1.39) 0.85 0.92 (0.56, 1.50) 0.73 
Bladder cancer 0.84 (0.63, 1.12) 0.23 0.95 (0.87, 1.05) 0.31 1.17 (0.58, 2.37) 0.65 0.94 (0.57, 1.43) 0.73 1.09 (0.61, 1.96) 0.76 
Brain cancer 1.02 (0.85, 1.23) 0.80 1.01 (0.95, 1.07) 0.76 0.96 (0.61, 1.52) 0.86 1.12 (0.80, 1.48) 0.57 1.18 (0.78, 1.78) 0.45 
Liver cancer 1.00 (0.80, 1.25) 0.98 1.03 (0.96, 1.10) 0.46 0.83 (0.47, 1.44) 0.50 0.94 (0.66, 1.36) 0.73 1.08 (0.69, 1.71) 0.73 
Lymphatic cancer 1.03 (0.91, 1.17) 0.62 1.00 (0.96, 1.04) 0.98 1.03 (0.76, 1.40) 0.86 1.04 (0.86, 1.28) 0.64 0.99 (0.76, 1.29) 0.94 
Other cancers 0.96 (0.87, 1.07) 0.47 0.96 (0.93, 1.00) 0.03 1.25 (0.97, 1.62) 0.09 1.00 (0.89, 1.20) 0.68 1.04 (0.85, 1.27) 0.69 
External causes 1.23 (1.03, 1.46) 0.03 1.04 (0.98, 1.10) 0.22 0.95 (0.61, 1.48) 0.83 1.07 (0.84, 1.45) 0.49 1.05 (0.75, 1.48) 0.76 
BMI = body mass index; CI = confidence interval; HR = hazard ratio; IVW = inverse variance weighted; MR = Mendelian randomization 
1Adjusted for secular trends (date of birth) and the first ten genetic principal components, estimates represent HR with each unit increase in BMI (kg/m2) 
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Table S9b. MR-Egger analysis of BMI on all-cause and cause-specific mortality in UK Biobank males of White British ancestry 
Cause of death 
IVW Intercept of MR-Egger MR-Egger Weighted median Weighted mode 
HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P 
All-cause 1.02 (0.98, 1.06) 0.28 0.99 (0.98, 1.00) 0.13 1.09 (0.99, 1.20) 0.07 1.02 (0.97, 1.11) 0.29 1.03 (0.95, 1.12) 0.42 
Cardiovascular disease 1.07 (0.99, 1.15) 0.11 0.99 (0.97, 1.02) 0.54 1.12 (0.93, 1.36) 0.23 1.04 (0.93, 1.19) 0.43 1.04 (0.88, 1.23) 0.65 
Coronary heart disease 1.09 (0.98, 1.21) 0.11 0.99 (0.96, 1.02) 0.51 1.18 (0.91, 1.53) 0.21 1.07 (0.94, 1.28) 0.32 1.10 (0.90, 1.35) 0.35 
Stroke 1.00 (0.81, 1.23) 0.98 1.00 (0.94, 1.07) 0.92 0.98 (0.58, 1.65) 0.93 0.98 (0.70, 1.26) 0.71 0.91 (0.59, 1.40) 0.66 
Aortic aneurysm 0.86 (0.62, 1.21) 0.39 1.06 (0.95, 1.18) 0.29 0.57 (0.25, 1.33) 0.19 0.66 (0.48, 1.33) 0.37 0.71 (0.38, 1.32) 0.28 
Other cardiovascular diseases  1.11 (0.93, 1.33) 0.24 0.97 (0.92, 1.03) 0.35 1.35 (0.86, 2.11) 0.19 1.14 (0.86, 1.52) 0.29 1.14 (0.81, 1.62) 0.45 
Respiratory diseases 1.03 (0.88, 1.20) 0.69 1.02 (0.97, 1.07) 0.52 0.92 (0.63, 1.35) 0.67 1.07 (0.77, 1.23) 0.83 0.87 (0.62, 1.22) 0.42 
Cancer 1.00 (0.95, 1.06) 0.98 0.99 (0.97, 1.01) 0.30 1.07 (0.93, 1.23) 0.33 1.03 (0.94, 1.12) 0.58 1.02 (0.91, 1.15) 0.69 
Lung cancer 0.94 (0.83, 1.06) 0.32 1.01 (0.97, 1.05) 0.52 0.86 (0.63, 1.17) 0.32 0.89 (0.77, 1.13) 0.47 0.85 (0.65, 1.11) 0.24 
Prostate cancer 0.91 (0.76, 1.09) 0.32 0.96 (0.91, 1.02) 0.20 1.19 (0.76, 1.86) 0.43 1.01 (0.76, 1.25) 0.81 1.05 (0.76, 1.45) 0.77 
Colorectal cancer 1.07 (0.91, 1.26) 0.40 1.01 (0.96, 1.06) 0.69 0.99 (0.66, 1.49) 0.98 1.00 (0.81, 1.34) 0.82 1.04 (0.73, 1.49) 0.82 
Pancreatic cancer 1.14 (0.93, 1.39) 0.21 1.02 (0.96, 1.09) 0.45 0.96 (0.58, 1.58) 0.86 0.96 (0.76, 1.44) 0.80 0.98 (0.66, 1.45) 0.93 
Stomach cancer 1.12 (0.84, 1.50) 0.42 0.98 (0.89, 1.07) 0.63 1.32 (0.64, 2.70) 0.45 1.45 (0.77, 2.04) 0.33 1.62 (0.86, 3.06) 0.14 
Oesophageal cancer 1.21 (0.99, 1.48) 0.06 0.97 (0.91, 1.04) 0.43 1.45 (0.89, 2.38) 0.14 1.17 (0.86, 1.62) 0.31 1.33 (0.85, 2.09) 0.22 
Malignant melanoma2 1.03 (0.74, 1.43) 0.85 1.02 (0.92, 1.13) 0.73 0.91 (0.40, 2.05) 0.81 1.14 (0.64, 1.76) 0.76 1.14 (0.61, 2.11) 0.68 
Kidney cancer 1.04 (0.79, 1.36) 0.77 1.02 (0.94, 1.11) 0.66 0.91 (0.46, 1.78) 0.77 1.06 (0.65, 1.47) 0.98 0.92 (0.55, 1.57) 0.77 
Bladder cancer 0.80 (0.58, 1.10) 0.17 0.93 (0.84, 1.03) 0.15 1.36 (0.61, 3.06) 0.45 0.90 (0.53, 1.53) 0.68 1.04 (0.54, 1.99) 0.91 
Brain cancer 1.12 (0.90, 1.40) 0.29 1.01 (0.95, 1.09) 0.69 1.02 (0.59, 1.75) 0.96 1.16 (0.74, 1.66) 0.58 1.33 (0.79, 2.21) 0.28 
Liver cancer 1.04 (0.78, 1.39) 0.78 0.98 (0.89, 1.07) 0.65 1.21 (0.59, 2.47) 0.60 1.29 (0.76, 1.86) 0.46 1.35 (0.75, 2.44) 0.32 
Lymphatic cancer 1.02 (0.87, 1.19) 0.80 0.99 (0.94, 1.04) 0.61 1.12 (0.76, 1.65) 0.57 1.02 (0.86, 1.39) 0.45 1.18 (0.85, 1.63) 0.32 
Other cancers 0.92 (0.80, 1.05) 0.22 0.95 (0.91, 0.99) 0.01 1.35 (0.97, 1.89) 0.07 1.06 (0.83, 1.28) 0.81 1.08 (0.84, 1.38) 0.57 
External causes 1.09 (0.88, 1.34) 0.42 1.05 (0.98, 1.12) 0.16 0.78 (0.47, 1.30) 0.34 0.90 (0.71, 1.32) 0.84 0.92 (0.62, 1.36) 0.67 
BMI = body mass index; CI = confidence interval; HR = hazard ratio; IVW = inverse variance weighted; MR = Mendelian randomization 
1Adjusted for secular trends (date of birth) and the first ten genetic principal components, estimates represent HR with each unit increase in BMI (kg/m2) 
2Estimates obtained for the causal effect of BMI on mortality from malignant melanoma in males only used 76/77 SNPs, as all men who died from malignant melanoma 
had a dosage of ‘0’ for one SNP (rs17024393); thus, providing no variation in mortality risk with this SNP. 
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Table S9c. MR-Egger analysis of BMI on all-cause and cause-specific mortality in UK Biobank females of White British ancestry 
Cause of death 
IVW Intercept of MR-Egger MR-Egger Weighted median Weighted mode 
HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P HR (95% CI)1 P 
All-cause 1.02 (0.96, 1.08) 0.50 1.01 (0.99, 1.03) 0.27 0.95 (0.82, 1.09) 0.45 1.00 (0.93, 1.09) 0.83 1.01 (0.92, 1.12) 0.80 
Cardiovascular disease 1.09 (0.94, 1.26) 0.27 1.03 (0.98, 1.08) 0.23 0.88 (0.61, 1.28) 0.51 0.90 (0.80, 1.22) 0.89 0.85 (0.64, 1.12) 0.25 
Coronary heart disease 1.10 (0.88, 1.37) 0.40 1.03 (0.96, 1.11) 0.34 0.86 (0.50, 1.49) 0.58 1.05 (0.74, 1.45) 0.82 1.25 (0.81, 1.93) 0.31 
Stroke 0.95 (0.72, 1.24) 0.68 1.05 (0.96, 1.14) 0.31 0.69 (0.35, 1.35) 0.27 0.85 (0.61, 1.27) 0.48 0.87 (0.54, 1.41) 0.57 
Other cardiovascular diseases  1.31 (1.01, 1.71) 0.05 1.01 (0.93, 1.10) 0.85 1.24 (0.64, 2.40) 0.53 1.29 (0.86, 1.96) 0.27 1.43 (0.84, 2.44) 0.19 
Respiratory diseases 1.03 (0.83, 1.28) 0.80 1.03 (0.96, 1.11) 0.39 0.83 (0.48, 1.43) 0.49 0.87 (0.65, 1.35) 0.68 0.89 (0.56, 1.39) 0.60 
Cancer 0.98 (0.92, 1.04) 0.54 1.01 (0.99, 1.03) 0.25 0.91 (0.78, 1.05) 0.19 0.96 (0.89, 1.08) 0.63 0.97 (0.87, 1.09) 0.61 
Lung cancer 1.02 (0.88, 1.17) 0.83 1.02 (0.98, 1.07) 0.34 0.87 (0.62, 1.23) 0.43 0.95 (0.78, 1.19) 0.70 0.90 (0.68, 1.21) 0.51 
Breast cancer 0.87 (0.76, 0.99) 0.03 0.98 (0.94, 1.03) 0.41 0.98 (0.71, 1.37) 0.92 0.92 (0.73, 1.10) 0.34 0.92 (0.70, 1.21) 0.54 
Pre-menopausal 0.83 (0.55, 1.27) 0.39 0.99 (0.86, 1.13) 0.85 0.92 (0.32, 2.61) 0.87 0.94 (0.45, 1.65) 0.69 1.01 (0.46, 2.22) 0.98 
Post-menopausal 0.87 (0.76, 1.00) 0.05 0.98 (0.94, 1.03) 0.42 0.99 (0.70, 1.41) 0.97 0.91 (0.72, 1.13) 0.35 0.92 (0.68, 1.23) 0.57 
Colorectal cancer 1.01 (0.80, 1.28) 0.92 1.03 (0.95, 1.11) 0.51 0.85 (0.47, 1.53) 0.58 1.26 (0.81, 1.52) 0.44 1.30 (0.82, 2.05) 0.26 
Pancreatic cancer 1.02 (0.82, 1.27) 0.87 1.03 (0.96, 1.11) 0.38 0.81 (0.47, 1.41) 0.46 1.08 (0.73, 1.47) 0.79 1.12 (0.76, 1.65) 0.58 
Ovarian cancer 1.16 (0.94, 1.42) 0.16 1.03 (0.96, 1.10) 0.39 0.95 (0.57, 1.57) 0.83 1.17 (0.83, 1.55) 0.45 1.20 (0.82, 1.76) 0.35 
Endometrial cancer 0.73 (0.49, 1.11) 0.14 1.02 (0.90, 1.17) 0.73 0.62 (0.22, 1.76) 0.36 0.58 (0.33, 1.12) 0.12 0.43 (0.17, 1.05) 0.07 
Oesophageal cancer 1.03 (0.70, 1.51) 0.88 1.03 (0.91, 1.17) 0.60 0.82 (0.31, 2.13) 0.67 0.89 (0.48, 1.59) 0.70 0.83 (0.35, 1.97) 0.68 
Malignant melanoma 1.44 (0.91, 2.26) 0.11 1.07 (0.92, 1.24) 0.37 0.89 (0.29, 2.78) 0.85 1.41 (0.58, 2.14) 0.75 1.06 (0.41, 2.71) 0.91 
Kidney cancer 0.77 (0.50, 1.18) 0.22 1.04 (0.90, 1.19) 0.58 0.58 (0.20, 1.70) 0.32 0.84 (0.38, 1.58) 0.57 0.80 (0.29, 2.21) 0.67 
Brain cancer 0.90 (0.66, 1.22) 0.50 1.00 (0.90, 1.10) 0.93 0.93 (0.43, 2.00) 0.85 1.03 (0.62, 1.69) 0.88 1.05 (0.58, 1.90) 0.87 
Liver cancer 0.96 (0.67, 1.39) 0.84 1.10 (0.98, 1.24) 0.10 0.47 (0.19, 1.18) 0.11 0.67 (0.41, 1.25) 0.27 0.47 (0.22, 1.01) 0.06 
Lymphatic cancer 1.05 (0.86, 1.29) 0.61 1.02 (0.96, 1.09) 0.53 0.91 (0.55, 1.51) 0.70 0.91 (0.70, 1.30) 0.79 0.86 (0.55, 1.33) 0.49 
Other cancers 1.03 (0.88, 1.22) 0.69 0.99 (0.94, 1.04) 0.70 1.11 (0.74, 1.68) 0.61 1.07 (0.85, 1.41) 0.44 1.10 (0.77, 1.57) 0.60 
External causes 1.59 (1.19, 2.12) 0.002 1.01 (0.92, 1.11) 0.77 1.44 (0.71, 2.94) 0.31 1.40 (0.89, 2.26) 0.10 1.37 (0.78, 2.42) 0.28 
BMI = body mass index; CI = confidence interval; HR = hazard ratio; IVW = inverse variance weighted; MR = Mendelian randomization 
1Adjusted for secular trends (date of birth) and the first ten genetic principal components, estimates represent HR with each unit increase in BMI (kg/m2) 
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Table S10a. Association between the weighted GRS (comprising 77 SNPs) and BMI in UK Biobank 
participants of White British ancestry additionally adjusting for confounding factors 
Sample N 
Effect estimate 
(95% CI)1 
P-value R2 (%)2 
Whole sample 265,633 0.107 (0.104, 0.110) <1.20x10-307 5.40 
Males  123,509 0.099 (0.095, 0.103) <1.20x10-307 6.22 
Females 142,124 0.114 (0.109, 0.118) <1.20x10-307 5.52 
BMI = body mass index; CI = confidence interval; GRS = genetic risk score; SNP = single nucleotide 
polymorphism 
1Effect estimate (and corresponding P-value) represents the change in BMI (kg/m2) per BMI-increasing 
allele in individuals of White British ancestry adjusted for the first ten genetic principal components, highest 
household occupation, education, smoking status, alcohol intake, physical activity and genotyping chip 
2Variance in BMI explained by the GRS
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Table S10b. MR analyses of all-cause and cause-specific mortality by BMI in UK Biobank participants of White British ancestry additionally adjusting for 
confounding factors 
Cause of death 
Whole sample Males Females 
HR (95% CI)1 P-value HR (95% CI)1 P-value HR (95% CI)1 P-value 
All-cause 1.02 (0.97, 1.07) 0.45 1.03 (0.96, 1.10) 0.41 1.00 (0.93, 1.08) 0.91 
Cardiovascular disease 1.14 (1.02, 1.27) 0.02 1.12 (0.98, 1.27) 0.10 1.22 (0.97, 1.53) 0.09 
Coronary heart disease 1.22 (1.05, 1.42) 0.01 1.23 (1.04, 1.45) 0.02 1.24 (0.83, 1.85) 0.30 
Stroke 0.98 (0.75, 1.29) 0.89 0.88 (0.61, 1.29) 0.52 1.12 (0.75, 1.68) 0.59 
Aortic aneurysm 0.85 (0.54, 1.32) 0.47 0.80 (0.48, 1.35) 0.41 - - 
Other cardiovascular diseases 1.15 (0.92, 1.45) 0.23 1.07 (0.80, 1.42) 0.66 1.37 (0.91, 2.06) 0.13 
Respiratory diseases 0.86 (0.68, 1.09) 0.21 0.82 (0.61, 1.10) 0.18 0.95 (0.63, 1.42) 0.79 
Cancer 0.97 (0.91, 1.04) 0.41 1.00 (0.91, 1.09) 0.94 0.95 (0.87, 1.04) 0.25 
Lung cancer 0.96 (0.81, 1.13) 0.60 0.95 (0.76, 1.19) 0.68 0.96 (0.75, 1.23) 0.76 
Prostate cancer - - 0.70 (0.53, 0.93) 0.01 - - 
Breast cancer - - - - 0.84 (0.69, 1.03) 0.09 
Pre-menopausal - - - - 0.77 (0.44, 1.37) 0.38 
Post-menopausal - - - - 0.85 (0.69, 1.05) 0.14 
Colorectal cancer 1.12 (0.92, 1.35) 0.25 1.19 (0.92, 1.54) 0.18 1.03 (0.78, 1.37) 0.84 
Pancreatic cancer 1.02 (0.81, 1.30) 0.84 1.04 (0.74, 1.46) 0.81 1.01 (0.72, 1.40) 0.97 
Stomach cancer 1.36 (0.89, 2.07) 0.15 1.36 (0.82, 2.26) 0.23 - - 
Ovarian cancer - - - - 1.16 (0.86, 1.57) 0.33 
Endometrial cancer - - - - 0.67 (0.35, 1.28) 0.23 
Oesophageal cancer 1.09 (0.82, 1.45) 0.55 1.22 (0.87, 1.71) 0.25 0.77 (0.43, 1.38) 0.39 
Malignant melanoma 1.08 (0.72, 1.60) 0.72 0.91 (0.54, 1.52) 0.71 1.41 (0.74, 2.68) 0.29 
Kidney cancer 0.96 (0.66, 1.38) 0.81 1.09 (0.70, 1.68) 0.70 0.67 (0.32, 1.37) 0.27 
Bladder cancer 0.82 (0.51, 1.31) 0.41 0.89 (0.52, 1.52) 0.66 - - 
Brain cancer 1.01 (0.77, 1.32) 0.95 1.34 (0.93, 1.92) 0.12 0.71 (0.47, 1.05) 0.09 
Liver cancer 0.94 (0.65, 1.36) 0.75 0.79 (0.48, 1.29) 0.34 1.21 (0.69, 2.11) 0.51 
Lymphatic cancer 1.03 (0.84, 1.26) 0.77 1.05 (0.80, 1.36) 0.74 1.01 (0.73, 1.40) 0.94 
Other cancers 0.95 (0.80, 1.12) 0.52 0.89 (0.71, 1.12) 0.32 1.02 (0.78, 1.34) 0.87 
External causes 1.41 (1.10, 1.81) 0.01 1.28 (0.93, 1.77) 0.13 1.71 (1.12, 2.59) 0.01 
BMI = body mass index; CI = confidence interval; HR = hazard ratio 
1Adjusted for secular trends (date of birth), the first ten genetic principal components, highest household occupation, education, smoking status, alcohol intake, physical 
activity and genotyping chip; estimates represent HR with each unit increase in BMI (kg/m2) 
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Table S11a. Association between the weighted GRS (comprising 70 SNPs, after excluding 7 genetic 
variants implicated as pleiotropic) and BMI in UK Biobank participants of White British ancestry 
Sample N 
Effect estimate 
(95% CI)1 
P-value R2 (%)2 
Whole sample 335,308 0.112 (0.109, 0.115) <1.20x10-307 1.68 
Males  154,967 0.105 (0.101, 0.109) <1.20x10-307 1.90 
Females 180,341 0.117 (0.112, 0.121) <1.20x10-307 1.57 
BMI = body mass index; CI = confidence interval; GRS = genetic risk score; SNP = single nucleotide 
polymorphism 
1Effect estimate (and corresponding P-value) represents the change in BMI (kg/m2) per BMI-increasing 
allele in individuals of White British ancestry adjusted for the first ten genetic principal components 
2Variance in BMI explained by the GRS 
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Table S11b. MR analyses of all-cause and cause-specific mortality by BMI in UK Biobank participants of White British ancestry using a GRS (comprising 70 SNPs, 
after excluding 7 genetic variants implicated as pleiotropic) 
Cause of death 
Whole sample Males Females 
HR (95% CI)1 P-value HR (95% CI)1 P-value HR (95% CI)1 P-value 
All-cause 1.03 (0.99, 1.07) 0.21 1.03 (0.98, 1.08) 0.29 1.02 (0.96, 1.09) 0.48 
Cardiovascular disease 1.11 (1.01, 1.21) 0.02 1.10 (0.99, 1.22) 0.09 1.14 (0.96, 1.36) 0.13 
Coronary heart disease 1.14 (1.02, 1.29) 0.03 1.13 (0.99, 1.30) 0.06 1.20 (0.90, 1.60) 0.22 
Stroke 0.97 (0.78, 1.19) 0.75 1.03 (0.77, 1.37) 0.86 0.90 (0.66, 1.23) 0.51 
Aortic aneurysm 0.78 (0.54, 1.14) 0.20 0.81 (0.52, 1.26) 0.36 - - 
Other cardiovascular disease 1.24 (1.03, 1.50) 0.03 1.12 (0.88, 1.42) 0.36 1.53 (1.10, 2.11) 0.01 
Respiratory diseases 1.06 (0.90, 1.26) 0.47 1.06 (0.86, 1.31) 0.57 1.07 (0.80, 1.44) 0.66 
Cancer 0.98 (0.93, 1.03) 0.44 0.99 (0.92, 1.07) 0.84 0.96 (0.89, 1.04) 0.35 
Lung cancer 0.95 (0.84, 1.08) 0.46 0.91 (0.77, 1.07) 0.25 1.02 (0.85, 1.23) 0.84 
Prostate cancer - - 0.84 (0.67, 1.05) 0.13 - - 
Breast cancer - - - - 0.81 (0.68, 0.97) 0.02 
Pre-menopausal - - - - 0.87 (0.50, 1.53) 0.64 
Post-menopausal - - - - 0.80 (0.67, 0.97) 0.02 
Colorectal cancer 1.05 (0.89, 1.24) 0.59 1.06 (0.85, 1.33) 0.59 1.02 (0.79, 1.32) 0.87 
Pancreatic cancer 1.04 (0.85, 1.27) 0.70 1.12 (0.85, 1.49) 0.42 0.96 (0.72, 1.28) 0.78 
Stomach cancer 1.22 (0.88, 1.69) 0.23 1.19 (0.80, 1.75) 0.39 - - 
Ovarian cancer - - - - 1.16 (0.89, 1.51) 0.28 
Endometrial cancer - - - - 0.60 (0.35, 1.04) 0.07 
Oesophageal cancer 1.23 (0.98, 1.56) 0.08 1.29 (0.99, 1.68) 0.06 1.07 (0.64, 1.79) 0.79 
Malignant melanoma 1.24 (0.86, 1.77) 0.24 1.03 (0.65, 1.62) 0.90 1.74 (0.95, 3.18) 0.07 
Kidney cancer 0.93 (0.69, 1.24) 0.62 1.03 (0.73, 1.44) 0.88 0.68 (0.38, 1.23) 0.20 
Bladder cancer 0.79 (0.53, 1.17) 0.23 0.75 (0.47, 1.18) 0.21 - - 
Brain cancer 1.03 (0.81, 1.30) 0.83 1.16 (0.85, 1.57) 0.36 0.86 (0.60, 1.25) 0.44 
Liver cancer 0.98 (0.72, 1.32) 0.88 1.06 (0.71, 1.59) 0.76 0.87 (0.55, 1.39) 0.56 
Lymphatic cancer 1.04 (0.88, 1.24) 0.63 1.09 (0.87, 1.35) 0.46 0.98 (0.74, 1.29) 0.87 
Other cancer 0.93 (0.81, 1.07) 0.31 0.85 (0.71, 1.03) 0.10 1.05 (0.84, 1.31) 0.67 
External causes 1.30 (1.04, 1.63) 0.02 1.13 (0.86, 1.49) 0.39 1.74 (1.18, 2.56) 0.005 
BMI = body mass index; CI = confidence interval; HR = hazard ratio 
1Adjusted for secular trends (date of birth) and  the first ten genetic principal components; estimates represent HR with each unit increase in BMI (kg/m2)  
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Figure S1: Exclusions made based on in-house QC parameters  
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Figure S2. MR-Egger analysis for mortality outcomes with any evidence for pleiotropy  
 
(a) other cancers in the whole UK Biobank sample 
 
 
 
(b) other cancers in males only 
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